Virtual Poster Session on AML - priME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session on AML

Key Data Presented During the 2019 Oncology Annual Meeting in Chicago

Not a member of My prIME? Join now for instant access.

This activity features presentations and downloadable slides highlighting the most recent updates in acute myeloid leukemia (AML) from featured experts in the field.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.75 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Jun 14, 2019

Expiration Date

Jun 14, 2020

Jorge Cortes, MD

Abstract #7010: Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: long-term analysis of a phase 2 randomized trial

Featured Expert: Jorge Cortes, MD

Jorge Cortes, MD

Abstract #7042: Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML)

Featured Expert: Jorge Cortes, MD

Marina Konopleva, MD

Abstract #TPS7063: MIRROS: an ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia

Featured Expert: Marina Konopleva, MD

  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Marina Konopleva, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States

This activity is designed for hematologists/oncologists and other healthcare professionals involved in the management of acute myeloid leukemia (AML).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the most recent key data in AML from the American oncology conference

Demonstrate greater competence in their ability to:

  • Apply key data from the American oncology conference to clinical practice, as appropriate

This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Jazz Pharmaceuticals; and Merck and Co., Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 0.75 hour(s)

To contact Postgraduate Institute for Medicine please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Cortes has disclosed that he has received consulting fees from Jazz Pharmaceuticals and Pfizer. He has performed contracted research for Jazz Pharmaceuticals and Pfizer through his institution. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Konopleva has disclosed that she has received consulting fees from Amgen; Genentech, Inc.; and Roche. She has performed contracted research for Ablynx, Amgen, Cellectis, Immunogen, Lilly, and Stemline. She also has less than 5% ownership interest in stocks from Reata Discovery. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Jamieson Bretz, PhD (senior director, content development) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by Array; AstraZeneca; F. Hoffmann-La Roche Ltd; Ipsen; Merck KGaA, Darmstadt, Germany; Pfizer; Servier; and Shire

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.